CL2019001683A1 - Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas. - Google Patents
Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.Info
- Publication number
- CL2019001683A1 CL2019001683A1 CL2019001683A CL2019001683A CL2019001683A1 CL 2019001683 A1 CL2019001683 A1 CL 2019001683A1 CL 2019001683 A CL2019001683 A CL 2019001683A CL 2019001683 A CL2019001683 A CL 2019001683A CL 2019001683 A1 CL2019001683 A1 CL 2019001683A1
- Authority
- CL
- Chile
- Prior art keywords
- activin
- treatment
- receptor antagonists
- myostatin
- obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA O ANTAGONISTAS DE RECEPTOR PARA EL USO EN LA MEJORA DE LA COMPOSICIÓN CORPORAL, POR EJEMPLO, PARA EL TRATAMIENTO DE LA ADIPOSIDAD CENTRAL, LA OBESIDAD O LA CONDICIÓN DE SOBREPESO Y LAS COMORBILIDADES RELACIONADAS. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA O ANTAGONISTAS DE RECEPTOR PARA EL TRATAMIENTO DE LA DIABETES TIPO II, AL MEJORAR EL CONTROL GLUCÉMICO, EN PARTICULAR, AL AUMENTAR LA SENSIBILIDAD A LA INSULINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437097P | 2016-12-21 | 2016-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001683A1 true CL2019001683A1 (es) | 2019-09-13 |
Family
ID=60972283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001683A CL2019001683A1 (es) | 2016-12-21 | 2019-06-19 | Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20190345251A1 (es) |
| EP (2) | EP3558361B1 (es) |
| JP (2) | JP7280825B2 (es) |
| KR (2) | KR20240147705A (es) |
| CN (2) | CN118105478A (es) |
| AU (1) | AU2017380844B2 (es) |
| BR (1) | BR112019012661A2 (es) |
| CA (1) | CA3042965A1 (es) |
| CL (1) | CL2019001683A1 (es) |
| DK (1) | DK3558361T3 (es) |
| ES (1) | ES3048908T3 (es) |
| FI (1) | FI3558361T3 (es) |
| HR (1) | HRP20251338T1 (es) |
| IL (1) | IL267471A (es) |
| JO (1) | JOP20190152A1 (es) |
| LT (1) | LT3558361T (es) |
| MX (2) | MX2019007581A (es) |
| PH (1) | PH12019501026A1 (es) |
| PL (1) | PL3558361T3 (es) |
| PT (1) | PT3558361T (es) |
| RS (1) | RS67393B1 (es) |
| TW (2) | TWI848773B (es) |
| WO (1) | WO2018116201A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| SMT202500263T1 (it) | 2015-09-15 | 2025-09-12 | Scholar Rock Inc | Anticorpi anti-pro-miostatina/miostatina latente e loro usi |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| KR102271635B1 (ko) | 2016-06-13 | 2021-07-06 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| DK3565592T5 (da) | 2017-01-06 | 2024-09-02 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
| GB201706857D0 (en) | 2017-04-28 | 2017-06-14 | Select Res Ltd | Health risk prediction tools |
| MX2020013899A (es) | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| JP7663559B2 (ja) | 2019-09-03 | 2025-04-16 | ノバルティス アーゲー | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 |
| US20240124541A1 (en) * | 2021-04-12 | 2024-04-18 | University of Florida Research Foundation, Incorprated | Compositions and methods for treating obesity |
| WO2022271867A1 (en) * | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| TW202323296A (zh) | 2021-08-27 | 2023-06-16 | 美商維紗妮絲生物公司 | 組合療法 |
| WO2023141525A2 (en) * | 2022-01-19 | 2023-07-27 | Versanis Bio, Inc. | Actrii antibody treatments |
| CA3265879A1 (en) | 2022-08-26 | 2024-02-29 | Versanis Bio, Inc. | ACTRII FIXED SINGLE-DOSE ANTIBODY TREATMENTS |
| TW202430247A (zh) | 2022-12-22 | 2024-08-01 | 美商供石公司 | 肌肉生長抑制素活化之選擇性及強效抑制劑 |
| WO2025027052A1 (en) | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| US8178488B2 (en) * | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| EP2440577A4 (en) * | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| MX340451B (es) * | 2009-09-09 | 2016-07-08 | Acceleron Pharma Inc | Antagonistas de actriib y dosificacion y usos de los mismos. |
| DK2726099T3 (en) * | 2011-07-01 | 2018-11-05 | Novartis Ag | Method of treating metabolic disorders |
| WO2013188448A2 (en) * | 2012-06-11 | 2013-12-19 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| TN2017000217A1 (en) * | 2014-12-08 | 2018-10-19 | Novartis Ag | Myostatin or activin antagonists for the treatment of sarcopenia |
| WO2016205370A1 (en) * | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| HK1254630A1 (zh) * | 2015-11-11 | 2019-07-26 | Novartis Ag | 肌抑素拮抗剂的用途、含有它们的组合及其用途 |
-
2017
- 2017-06-16 JO JOP/2019/0152A patent/JOP20190152A1/ar unknown
- 2017-12-20 CN CN202311527567.XA patent/CN118105478A/zh active Pending
- 2017-12-20 EP EP17829315.5A patent/EP3558361B1/en active Active
- 2017-12-20 BR BR112019012661A patent/BR112019012661A2/pt unknown
- 2017-12-20 PL PL17829315.5T patent/PL3558361T3/pl unknown
- 2017-12-20 HR HRP20251338TT patent/HRP20251338T1/hr unknown
- 2017-12-20 EP EP25196508.3A patent/EP4659804A2/en active Pending
- 2017-12-20 CN CN201780078980.9A patent/CN110087684B/zh active Active
- 2017-12-20 US US16/471,756 patent/US20190345251A1/en not_active Abandoned
- 2017-12-20 RS RS20251104A patent/RS67393B1/sr unknown
- 2017-12-20 KR KR1020247032712A patent/KR20240147705A/ko active Pending
- 2017-12-20 FI FIEP17829315.5T patent/FI3558361T3/fi active
- 2017-12-20 JP JP2019533642A patent/JP7280825B2/ja active Active
- 2017-12-20 MX MX2019007581A patent/MX2019007581A/es unknown
- 2017-12-20 WO PCT/IB2017/058199 patent/WO2018116201A1/en not_active Ceased
- 2017-12-20 LT LTEPPCT/IB2017/058199T patent/LT3558361T/lt unknown
- 2017-12-20 DK DK17829315.5T patent/DK3558361T3/da active
- 2017-12-20 ES ES17829315T patent/ES3048908T3/es active Active
- 2017-12-20 KR KR1020197020340A patent/KR20190097138A/ko not_active Ceased
- 2017-12-20 PT PT178293155T patent/PT3558361T/pt unknown
- 2017-12-20 CA CA3042965A patent/CA3042965A1/en active Pending
- 2017-12-20 AU AU2017380844A patent/AU2017380844B2/en active Active
- 2017-12-21 TW TW112127021A patent/TWI848773B/zh active
- 2017-12-21 TW TW106144972A patent/TWI812606B/zh active
-
2019
- 2019-05-09 PH PH12019501026A patent/PH12019501026A1/en unknown
- 2019-06-18 IL IL267471A patent/IL267471A/en unknown
- 2019-06-19 CL CL2019001683A patent/CL2019001683A1/es unknown
- 2019-06-21 MX MX2024001135A patent/MX2024001135A/es unknown
-
2021
- 2021-03-02 US US17/190,356 patent/US20210363263A1/en active Pending
-
2022
- 2022-12-22 JP JP2022205197A patent/JP2023052026A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001683A1 (es) | Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas. | |
| CL2020002796A1 (es) | Derivados de gip y usos de estos | |
| PE20210162A1 (es) | Analogos de incretina y sus usos | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| CO2017003487A2 (es) | Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos | |
| UY35072A (es) | Derivados de exendina-4 como agonistas duales de GLP1/glucagón | |
| CL2014002556A1 (es) | Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. | |
| CO7400885A2 (es) | Análogos de glucagón | |
| CL2014000458A1 (es) | Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades. | |
| PH12014502857A1 (en) | Analogs of glucagon exhibiting gip receptor activity | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| MX2016004907A (es) | Analogos del glucagon. | |
| MX2014015558A (es) | Analogos de glucagon que exhiben actividad del receptor gip. | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| UY35233A (es) | Derivados de Exendina-4 como agonistas dobles de GLP1/GIP o triples de GLP1/GIP/Glucagón | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| CL2016002809A1 (es) | Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión. | |
| MX381944B (es) | Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos. | |
| MX2018005305A (es) | Nuevos antiestrogenos heterociclicos. | |
| PE20240087A1 (es) | Composicion para el control de enfermedades en plantas | |
| MX379289B (es) | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. |